The FDA reviews odronextamab's application for relapsed lymphoma, highlighting trial enrollment issues but confirming safety and efficacy.

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday after market hours. Here’s ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

LONG BEACH, Calif. -- Depletion of a payment assistance program has translated into worse vision outcomes for older patients ...